Infectiology

Quofenix^®

Quofenix^® is a broad-spectrum fluoroquinolone antibiotic.¹

Quofenix^® (delafloxacin) is an antibiotic from the fluoroquinolone group that is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI^*) and community-acquired pneumonia (CAP^**) in adults as monotherapy. In addition to its very broad spectrum of activity, both in the gram-negative and the gram-positive spectrum (incl. MRSA)¹, the unique anionic structure of delafloxacin gives it increased intracellular penetration and enhanced bactericidal activity under acidic conditions that characterize the environment at a number of infection sites.^2,3

With respect to known side effects from the class of fluoroquinolones, Quofenix^® has a favorable tolerability profile because, unlike other fluoroquinolones, it shows no evidence of QT time prolongation or phototoxicity.⁴ Quofenix^® is available as both an i.v. formulation and a tablet, allowing for optimal patient management.

^* ABSSSI = acute bacterial skin and skin structure infections, ^** CAP = community-acquired pneumonia

References: 1 Drug information, 2 Jorgensen SCJ, et al. lnfect Dis Ther. 2018;7(2):197-217, 3 Lemaire S, et al. Antimicrob Agents Chemother. 2011;55(2):649-658, 4 Lodise T. et al., Open Forum lnfect Dis 2018; 5(10)

AT-WEB-17-10-2021